Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557214 | 0.83 | CYP19A1 (0.55) | CYP19A1POLBALDH1A1GAAFNTA | |
| SCHEMBL13475616 | 0.75 | CYP19A1 (0.55) | CYP19A1 | |
| SCHEMBL2818075 | 0.71 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL2824079 | 0.71 | CYP19A1 (0.43) | CYP19A1POLBFNTAFNTBPGGT1B | |
| SCHEMBL2818060 | 0.71 | CYP19A1 (0.43) | CYP19A1POLBFNTAFNTBPGGT1B | |
| SCHEMBL11561010 | 0.71 | CYP19A1 (0.47) | CYP19A1POLBALDH1A1GAAFNTA | |
| SCHEMBL9633309 | 0.69 | CYP19A1 (1.00) | CYP19A1POLBGAAMAPT | |
| SCHEMBL9634666 | 0.68 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL9367361 | 0.66 | CYP19A1 (0.69) | CYP19A1POLBMAPT | |
| SCHEMBL10372914 | 0.66 | CYP19A1 (0.50) | CYP19A1POLBFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP19A1 11/4885POLB 552/4885ALDH1A1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.